|
1
|
Ferlay J, Soerjomataram I, Ervik M,
Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and
Bray F: Cancer Incidence and Mortality World wide
GLOBOCAN2012.v10.2013. https://publications.iarc.fr/Databases/Iarc-Cancerbases/GLOBOCAN-2012-Estimated-Cancer-Incidence-Mortality-And-Prevalence-Worldwide-In-2012-V1.0-2012.
|
|
2
|
Ljungberg B, Cowan NC, Hanbury DC, Hora M,
Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF and Sinescu IC;
European Association of Urology Guideline Group: EAU guidelines on
renal cell carcinoma: The 2010 update. Eur Urol. 58:398–406. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rini BI, Campbell SC and Escudier B: Renal
cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Walsh N, Larkin A, Kennedy S, Connolly L,
Ballot J, Ooi W, Gullo G, Crown J, Clynes M and O'Driscoll L:
Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and
ABCC1 (MRP-1) in renal cell carcinoma. BMC Urol. 9:62009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Poletto V, Rosti V, Biggiogera M, Guerra
G, Moccia F and Porta C: The role of endothelial colony forming
cells in kidney cancer's pathogenesis, and in resistance to
anti-VEGFR agents and mTOR inhibitors: A speculative review. Crit
Rev Oncol Hematol. 132:89–99. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bedke J, Stühler V, Stenzl A and Brehmer
B: Immunotherapy for kidney cancer: Status quo and the future. Curr
Opin Urol. 28:8–14. 2018.
|
|
7
|
Tomczak K, Czerwińska P and Wiznerowicz M:
The Cancer Genome Atlas (TCGA): An immeasurable source of
knowledge. Contemp Oncol (Pozn). 19A:A68–A77. 2015.
|
|
8
|
Bosc DG, Graham KC, Saulnier RB, Zhang C,
Prober D, Gietz RD and Litchfield DW: Identification and
characterization of CKIP-1, a novel pleckstrin homology
domain-containing protein that interacts with protein kinase CK2. J
Biol Chem. 275:14295–14306. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Safi A, Vandromme M, Caussanel S, Valdacci
L, Baas D, Vidal M, Brun G, Schaeffer L and Goillot E: Role for the
pleckstrin homology domain-containing protein CKIP-1 in
phosphatidylinositol 3-kinase-regulated muscle differentiation. Mol
Cell Biol. 24:1245–1255. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Olsten ME, Canton DA, Zhang C, Walton PA
and Litchfield DW: The Pleckstrin homology domain of CK2
interacting protein-1 is required for interactions and recruitment
of protein kinase CK2 to the plasma membrane. J Biol Chem.
279:42114–42127. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nie J, Liu L, He F, Fu X, Han W and Zhang
L: CKIP-1: A scaffold protein and potential therapeutic target
integrating multiple signaling pathways and physiological
functions. Ageing Res Rev. 12:276–281. 2013. View Article : Google Scholar
|
|
12
|
Tokuda E, Fujita N, Oh-hara T, Sato S,
Kurata A, Katayama R, Itoh T, Takenawa T, Miyazono K and Tsuruo T:
Casein kinase 2-interacting protein-1, a novel Akt pleckstrin
homology domain-interacting protein, down-regulates PI3K/Akt
signaling and suppresses tumor growth in vivo. Cancer Res.
67:9666–9676. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang L, Xing G, Tie Y, Tang Y, Tian C, Li
L, Sun L, Wei H, Zhu Y and He F: Role for the pleckstrin homology
domain-containing protein CKIP-1 in AP-1 regulation and apoptosis.
EMBO J. 24:766–778. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Canton DA, Olsten ME, Kim K, Doherty-Kirby
A, Lajoie G, Cooper JA and Litchfield DW: The pleckstrin homology
domain-containing protein CKIP-1 is involved in regulation of cell
morphology and the actin cytoskeleton and interaction with actin
capping protein. Mol Cell Biol. 25:3519–3534. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Canton DA, Olsten ME, Niederstrasser H,
Cooper JA and Litchfield DW: The role of CKIP-1 in cell morphology
depends on its interaction with actin-capping protein. J Biol Chem.
281:36347–36359. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang L, Xia X, Zhang M, Wang Y, Xing G,
Yin X, Song L, He F and Zhang L: Integrated analysis of genomics
and proteomics reveals that CKIP-1 is a novel macrophage migration
regulator. Biochem Biophys Res Commun. 436:382–387. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang L, Wang Y, Xiao F, Wang S, Xing G,
Li Y, Yin X, Lu K, Wei R, Fan J, et al: CKIP-1 regulates macrophage
proliferation by inhibiting TRAF6-mediated Akt activation. Cell
Res. 24:742–761. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lu K, Yin X, Weng T, Xi S, Li L, Xing G,
Cheng X, Yang X, Zhang L and He F: Targeting WW domains linker of
HECT-type ubiquitin ligase Smurf1 for activation by CKIP-1. Nat
Cell Biol. 10:994–1002. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang Y, Nie J, Wang Y and Zhang L, Lu K,
Xing G, Xie P, He F and Zhang L: CKIP-1 couples Smurf1 ubiquitin
ligase with Rpt6 subunit of proteasome to promote substrate
degradation. EMBO Rep. 13:1004–1011. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang P, Zhou C, Lu C, Li W, Li W, Jing B,
Chen W, Zha Y, Zhang P, Bai C, et al: PLEKHO2 is essential for
M-CSF-dependent macrophage survival. Cell Signal. 37:115–122. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang G, Guo B, Wu H, Tang T, Zhang BT,
Zheng L, He Y, Yang Z, Pan X, Chow H, et al: A delivery system
targeting bone formation surfaces to facilitate RNAi-based anabolic
therapy. Nat Med. 18:307–314. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Koskimaki JE, Rosca EV, Rivera CG, Lee E,
Chen W, Pandey NB and Popel AS: Serpin-derived peptides are
antiangiogenic and suppress breast tumor xenograft growth. Transl
Oncol. 5:92–97. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nie J, Liu L, Xing G, Zhang M, Wei R, Guo
M, Li X, Xie P, Li L, He F, et al: CKIP-1 acts as a colonic tumor
suppressor by repressing oncogenic Smurf1 synthesis and promoting
Smurf1 autodegradation. Oncogene. 33:3677–3687. 2014. View Article : Google Scholar
|
|
24
|
Alvarez C, Aravena A, Tapia T, Rozenblum
E, Solís L, Corvalán A, Camus M, Alvarez M, Munroe D, Maass A, et
al: Different Array CGH profiles within hereditary breast cancer
tumors associated to BRCA1 expression and overall survival. BMC
Cancer. 16:2192016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gong W, Li J, Chen Z, Huang J, Chen Q, Cai
W, Liu P and Huang H: Polydatin promotes Nrf2-ARE anti-oxidative
pathway through activating CKIP-1 to resist HG-induced
up-regulation of FN and ICAM-1 in GMCs and diabetic mice kidneys.
Free Radic Biol Med. 106:393–405. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhan Y, Xie P, Li D, Li L, Chen J, An W,
Zhang L and Zhang C: Deficiency of CKIP-1 aggravates high-fat
diet-induced fatty liver in mice. Exp Cell Res. 355:40–46. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Burgess MR, Hwang E, Mroue R, Bielski CM,
Wandler AM, Huang BJ, Firestone AJ, Young A, Lacap JA, Crocker L,
et al: KRAS allelic imbalance enhances fitness and modulates MAP
kinase dependence in cancer. Cell. 168:817–829. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBio-Portal. Sci Signal. 6:112013. View Article : Google Scholar
|
|
30
|
Vinci M, Gowan S, Boxall F, Patterson L,
Zimmermann M, Court W, Lomas C, Mendiola M, Hardisson D and Eccles
SA: Advances in establishment and analysis of three-dimensional
tumor spheroid-based functional assays for target validation and
drug evaluation. BMC Biol. 10:292012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Feng L, Sun X, Csizmadia E, Han L, Bian S,
Murakami T, Wang X, Robson SC and Wu Y: Vascular CD39/ENTPD1
directly promotes tumor cell growth by scavenging extracellular
adenosine triphosphate. Neoplasia. 13:206–216. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
33
|
Leary S: AVMA Guidelines for the
Euthanasia of Animals: 2013 Edition. 2013, https://www.avma.org/KB/Policies/Documents/euthanasia.pdf.
|
|
34
|
National Research Council: Guide for the
Care and Use of Laboratory Animals: Eighth Edition. The National
Academies Press; Washington, DC: 2011, https://grants.nih.gov/grants/olaw/Guide-for-the-Care-and-Use-of-Laboratory-Animals.pdf.
Ilar Journal 56 NP-NP, 2015 https://doi.org/10.1093/ilar/ilv024.
|
|
35
|
Patel SJ, Sanjana NE, Kishton RJ,
Eidizadeh A, Vodnala SK, Cam M, Gartner JJ, Jia L, Steinberg SM,
Yamamoto TN, et al: Identification of essential genes for cancer
immunotherapy. Nature. 548:537–542. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhao D, Lu X, Wang G, Lan Z, Liao W, Li J,
Liang X, Chen JR, Shah S, Shang X, et al: Synthetic essentiality of
chromatin remodelling factor CHD1 in PTEN-deficient cancer. Nature.
542:484–488. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gong M, Xu Y, Dong W, Guo G, Ni W, Wang Y,
Wang Y and An R: Expression of Opa interacting protein 5 (OIP5) is
associated with tumor stage and prognosis of clear cell renal cell
carcinoma. Acta Histochem. 115:810–815. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ma HW, Xie M, Sun M, Chen TY, Jin RR, Ma
TS, Chen QN, Zhang EB, He XZ, De W, et al: The pseudogene derived
long noncoding RNA DUXAP8 promotes gastric cancer cell
proliferation and migration via epigenetically silencing PLEKHO1
expression. Oncotarget. 8:52211–52224. 2016.
|
|
39
|
Zhao B, Ye X, Yu J, Li L, Li W, Li S, Yu
J, Lin JD, Wang CY, Chinnaiyan AM, et al: TEAD mediates
YAP-dependent gene induction and growth control. Genes Dev.
22:1962–1971. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hao Y, Chun A, Cheung K, Rashidi B and
Yang X: Tumor suppressor LATS1 is a negative regulator of oncogene
YAP. J Biol Chem. 283:5496–5509. 2008. View Article : Google Scholar
|
|
41
|
Zhao B, Li L, Tumaneng K, Wang CY and Guan
KL: A coordinated phosphorylation by Lats and CK1 regulates YAP
stability through SCF(beta-TRCP). Genes Dev. 24:72–85. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Maugeri-Saccà M and De Maria R: The Hippo
pathway in normal development and cancer. Pharmacol Ther.
186:60–72. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ando T, Charindra D, Shrestha M, Umehara
H, Ogawa I, Miyauchi M and Takata T: Tissue inhibitor of
metalloproteinase-1 promotes cell proliferation through YAP/TAZ
activation in cancer. Oncogene. 37:263–270. 2018. View Article : Google Scholar
|
|
44
|
Lei Q-Y, Zhang H, Zhao B, Zha ZY, Bai F,
Pei XH, Zhao S, Xiong Y and Guan KL: TAZ promotes cell
proliferation and epithelial-mesenchymal transition and is
inhibited by the hippo pathway. Mol Cell Biol. 28:2426–2436. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu C-Y, Zha Z-Y, Zhou X, Zhang H, Huang
W, Zhao D, Li T, Chan SW, Lim CJ, Hong W, et al: The hippo tumor
pathway promotes TAZ degradation by phosphorylating a phosphodegron
and recruiting the SCF{beta}-TrCP E3 ligase. J Biol Chem.
285:37159–37169. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Bubici C and Papa S: JNK signalling in
cancer: In need of new, smarter therapeutic targets. Br J
Pharmacol. 171:24–37. 2014. View Article : Google Scholar :
|
|
47
|
Chang Q, Zhang Y, Beezhold KJ, Bhatia D,
Zhao H, Chen J, Castranova V, Shi X and Chen F: Sustained JNK1
activation is associated with altered histone H3 methylations in
human liver cancer. J Hepatol. 50:323–333. 2009. View Article : Google Scholar
|
|
48
|
Barbarulo A, Iansante V, Chaidos A, Naresh
K, Rahemtulla A, Franzoso G, Karadimitris A, Haskard DO, Papa S and
Bubici C: Poly(ADP-ribose) polymerase family member 14 (PARP14) is
a novel effector of the JNK2-dependent pro-survival signal in
multiple myeloma. Oncogene. 32:4231–4242. 2013. View Article : Google Scholar
|
|
49
|
Takahashi H, Ogata H, Nishigaki R, Broide
DH and Karin M: Tobacco smoke promotes lung tumorigenesis by
triggering IKKbeta- and JNK1-dependent inflammation. Cancer Cell.
17:89–97. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Luan L, Zhao Y, Xu Z, Jiang G, Zhang X,
Fan C, Liu D, Zhao H, Xu K, Wang M, et al: Diversin increases the
proliferation and invasion ability of non-small-cell lung cancer
cells via JNK pathway. Cancer Lett. 344:232–238. 2014. View Article : Google Scholar
|
|
51
|
Liu Q, Tao B, Liu G, Chen G, Zhu Q, Yu Y,
Yu Y and Xiong H: Thromboxane A2 receptor inhibition suppresses
multiple myeloma cell proliferation by inducing p38/c-Jun
N-terminal kinase (JNK) mitogen-activated protein kinase
(MAPK)-mediated G2/M progression delay and cell apoptosis. J Biol
Chem. 291:4779–4792. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Alameda JP, Fernández-Aceñero MJ,
Moreno-Maldonado R, Navarro M, Quintana R, Page A, Ramírez A, Bravo
A and Casanova ML: CYLD regulates keratinocyte differentiation and
skin cancer progression in humans. Cell Death Dis. 2:e2082011.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Gao Y, Tao J, Li MO, Zhang D, Chi H,
Henegariu O, Kaech SM, Davis RJ, Flavell RA and Yin Z: JNK1 is
essential for CD8+ T cell-mediated tumor immune
surveillance. J Immunol. 175:5783–5789. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Xiao X, Jiang K, Xu Y, Peng H, Wang Z, Liu
S and Zhang G: (-)-Epigallocatechin-3-gallate induces cell
apoptosis in chronic myeloid leukaemia by regulating
Bcr/Abl-mediated p38-MAPK/JNK and JAK2/STAT3/AKT signalling
pathways. Clin Exp Pharmacol Physiol. 46:126–136. 2019. View Article : Google Scholar
|
